Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

Patrick Campbell

Diabetes Dialogue: US Launch of Sequel Twiist AID System

In a live update from the American Diabetes Association (ADA) 85th Scientific Sessions in Chicago, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, shared their enthusiasm for the upcoming July 7 launch of the Sequel Twiist insulin pump. 

Designed with input from the open-source Loop movement, Twiist represents a significant advancement in automated insulin delivery and reflects a shift toward more flexible, patient-centered technology. One of the most notable features is the pump’s ability to set glucose targets as low as 87 mg/dL, which is the lowest available among current commercial pumps, according to Sequel Med Tech. 

In addition, Twiist introduces a "Premium Preset" function that can temporarily lower the target even further, to 67 mg/dL, for up to an hour before meals. This feature is designed to help smooth out post-meal spikes without increasing the risk of hypoglycemia, and it resets automatically if no carbs are entered, allowing for real-world flexibility without added burden.

Isaacs and Bellini also highlighted the system’s meal absorption feature, which lets users choose from three absorption profiles to match the type of meal they're having. Whether the meal is rapidly absorbed like a sugary snack, a standard mixed meal, or one that digests slowly over hours like pizza, the algorithm adjusts insulin delivery accordingly. This not only accounts for food variability but does so with a level of automation that aligns with how people actually live their lives.

Twiist also includes improved occlusion detection and will be distributed through pharmacies rather than through durable medical equipment channels, making access more straightforward. Hosts point out users can try the pump without committing to a full 4-year DME cycle, an appealing option for those curious to explore new technology without disrupting their existing care.

Bellini praised the design and flexibility of Twiist, calling it a "brilliant" system that meets patients where they are. Isaacs added that the innovation is especially inspiring given its roots in the DIY community, born out of a desire to move the field forward faster. With FDA clearance secured and distribution beginning through Byram Pharmacy, Sequel’s Twiist is poised to offer a fresh option in the growing landscape of automated insulin delivery.

Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others.

Podcasts

Hosts discuss the US launch of the Twiist from Sequel Med Tech and what it means for care providers and people with diabetes. 

The second quarter of 2025 brought a steady stream of momentum in cardiology, with developments spanning early-stage innovation, late-phase trial results, and new FDA approvals. This quarter’s recap includes 3 key regulatory milestones—including a major hypertension approval and a fast-tracked gene editing therapy—as well as 3 headline-making trial readouts that challenged, confirmed, or extended the evidence base in high-risk populations.

 delivered 3 episodes from the frontlines of ACC, Heart in Diabetes, and beyond—offering expert commentary on treatment sequencing, cardiorenal strategies, and emerging approaches in ATTR-CM. Here’s a look at what mattered most this past quarter in cardiovascular care.

FDA Grants Fast Track Designation to VERVE-102 Gene Therapy

On April 11, 2025, the FDA awarded Fast Track designation to Verve Therapeutics’ VERVE-102 gene editing medicine to lower low-density lipoprotein cholesterol (LDL-C) levels in individuals with hyperlipidemia and high cardiovascular risk. The regulatory agency cleared the Investigational New Drug (IND) application for VERVE-102 in March 2025, when the company provided interim data from the dose–escalation part of the Phase 1b Heart-2 trial.

FDA Accepts NDA Submission for Oral Semaglutide 25 mg

On May 2, 2025, Novo Nordisk announced the FDA accepted its NDA for a once-daily 25 mg oral formulation of semaglutide (Wegovy) for chronic weight management in adults with obesity or overweight. Based on Phase 3 OASIS 4 trial results, the pill showed significant efficacy in reducing weight in patients with at least one comorbidity. According to Novo Nordisk, this could become the first oral GLP-1 therapy approved for obesity treatment. The drug also aims to reduce cardiovascular risk in patients with established heart disease. The FDA decision is expected in Q4 2025.

FDA Approves Triple Combination Drug GMRx2 (Widaplik) for Hypertension Treatment

On June 9, 2025, the FDA approved GMRx2 (Widaplik), the first single-pill triple combination therapy—telmisartan, amlodipine, and indapamide—approved for initial treatment of hypertension in adults likely needing multiple drugs. Based on positive results from 2 phase 3 trials and the VERONICA study, Widaplik demonstrated superior blood pressure control and good tolerability. According to George Medicines, the pill's design aligns with global guidelines recommending early use of combination therapy. A US launch is expected in Q4 2025.

VERVE-102 Safely Cuts LDL-C Levels in Early Phase 1b Results

On April 14, 2025, Verve Therapeutics announced data from their phase 1b Heart-2 trial of VERVE-102 for the treatment of patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD). A single infusion of the in vivo gene editing medicine achieved dose-dependent reductions in blood PCSK9 and LDL-C, with a mean LDL-C reduction of ≥50% and a maximum decrease of nearly 70% at the highest dose.

Phase 3 Trial Results Announced for Sotatercept-csrk in Pulmonary Arterial Hypertension

On June 23, 2025, Merck announced positive topline results from the Phase 3 HYPERION trial, showing sotatercept-csrk (WINREVAIR) significantly reduced time to clinical worsening in newly diagnosed PAH patients at intermediate or high risk. Based on a composite primary endpoint, the trial met its goal, with additional benefits seen in walking distance, NT-proBNP levels, and functional class. According to Merck, these findings extend sotatercept’s evidence base to earlier-stage patients, building on prior success in advanced PAH. On July 02, 2025, Merck announced the FDA’s acceptance of their BLA for a label expansion, which was granted Priority Review.

ACHIEVE: Spironolactone Fails to Reduce Cardiovascular Risk in Dialysis Patients

On June 6, 2025, results from the ACHIEVE trial presented at ERA 2025 showed that spironolactone did not significantly reduce cardiovascular death or heart failure hospitalization in dialysis patients. Based on data from over 2,500 participants, the primary outcome occurred in 20.5% of the spironolactone group vs. 21.6% in the placebo group (HR 0.92; 

 = .35). According to investigators, the findings challenge earlier studies suggesting large cardioprotective benefits. Additionally, spironolactone was associated with a higher rate of severe hyperkalemia, occurring in 6.6% of patients.

During the second quarter of 2025, Don’t Miss a Beat released a trio of episodes, including a pair of in-person episodes from the floor at the American College of Cardiology and the Heart in Diabetes meeting. Check out our episode summaries below!

Treatment Sequencing in New Era of Heart Failure Management

In this episode recorded at ACC 2025, the hosts examine the expanding treatment landscape for HFpEF, advocating for early combination therapy using SGLT2 inhibitors, MRAs, and incretin-based drugs to improve outcomes. They debate rapid versus risk-based implementation, highlight phenotyping for tailored care, and discuss upcoming trials and the promise of fixed-dose combinations to enhance adherence.

CONFIDENCE Trial and Combination T2D, CKD Therapy at Heart in Diabetes 2025

In this episode, the hosts review findings from the CONFIDENCE trial showing that combination therapy with finerenone and empagliflozin significantly outperformed either drug alone in reducing albuminuria in patients with CKD and type 2 diabetes. They discuss the trial’s design, safety profile, and implications for rapid implementation strategies and future fixed-dose combination treatments in cardiorenal care.

Don't Miss a Beat: Navigating the ATTR-CM Care Landscape, With Ahmad Masri, MD

In this episode, the hosts and their guest discuss major advances in treating transthyretin amyloid cardiomyopathy, highlighting FDA-approved agents like tafamidis, acoramidis, and vutrisiran, while examining challenges such as residual risk, late-stage symptom limitations, and lack of head-to-head data. They also explore future strategies including amyloid-clearing therapies and early intervention trials like ACT-EARLY, which could shift the focus toward prevention in high-risk patients.

Articles

The second quarter of 2025 saw significant advancements in cardiology, including key FDA approvals and trial results. Notable regulatory milestones included the Fast Track designation for VERVE-102 gene therapy, the acceptance of an NDA for oral semaglutide, and the approval of the triple combination drug GMRx2 for hypertension. Trial updates highlighted the efficacy of VERVE-102 in reducing LDL-C levels, positive results for sotatercept-csrk in pulmonary arterial hypertension, and the lack of cardiovascular benefit from spironolactone in dialysis patients. Additionally, expert discussions on treatment strategies were featured in "Don't Miss a Beat" episodes.

Our recap of Q2 2025 in cardiology spotlights 3 FDA headlines, trial news, and new episodes of Don't Miss a Beat.

Q2 2025 Recap: Cardiology News and Updates

The second quarter of 2025 brought meaningful developments in endocrinology, from FDA actions to clinical breakthroughs spotlighted at major meetings. Several regulatory milestones signaled progress for patients across the spectrum of endocrine disorders, including expanded access to CGM technology, new formulations for adrenal insufficiency, and a broader treatment label for Cushing’s syndrome.

Novo Nordisk’s NDA for 25 mg oral semaglutide also marked a potential turning point in obesity care, with the first oral GLP-1 formulation for weight management now under review. Meanwhile, June’s ADA Scientific Sessions capped the quarter with a surge of new data on incretin therapies, obesity drugs, and diabetes technology—many with practice-changing potential.

Here’s a look back at the most impactful regulatory updates and conference highlights shaping the future of endocrine care.

On April 10, 2025, the FDA cleared Dexcom’s G7 15-day continuous glucose monitoring (CGM) system for adults with diabetes, making it the longest-lasting and most accurate CGM approved in the U.S. Based on clinical data showing a MARD of 8.0%, the G7 15 Day demonstrated excellent accuracy and user satisfaction. According to Dexcom, the system offers features like Apple Watch integration, waterproof sensors, and extended wear with a 12-hour grace period for sensor changes. The company plans to ensure compatibility with insulin pump systems ahead of its US launch in late 2025.

FDA Approves Label Expansion for Osilodrostat for Cushing's Syndrome

On April 16, 2025, the FDA approved Recordati’s sNDA for osilodrostat (Isturisa), expanding its indication to include adults with endogenous Cushing’s syndrome who are not surgical candidates or for whom surgery was not curative. Previously approved only for Cushing’s disease, the broader label is supported by data from the LINC 3 and LINC 4 trials showing sustained cortisol reduction and clinical improvement. According to Recordati, osilodrostat offers a vital option for managing hypercortisolemia and preventing severe complications. 

On May 2, 2025, Novo Nordisk announced the FDA accepted its NDA for a once-daily 25 mg oral formulation of semaglutide for chronic weight management in adults with obesity or overweight and at least one comorbidity. Based on results from the 64-week OASIS 4 trial, the oral semaglutide demonstrated significant weight loss and cardiovascular risk reduction. According to Novo Nordisk, this could become the first oral GLP-1 therapy approved for obesity. If approved, it would expand individualized treatment options beyond injectable formulations. An FDA decision is expected in Q4 2025.

FDA Approves Hydrocortisone Oral Solution for Adrenal Insufficiency

On May 28, 2025, the FDA approved Eton Pharmaceuticals’ hydrocortisone oral solution (KHINDIVI) for pediatric patients aged 5 and older with adrenocortical insufficiency, marking the first liquid formulation approved for this use. Designed for accurate, individualized dosing, the 1 mg/mL solution helps patients who have difficulty swallowing pills. According to Eton, this ready-to-use formulation eliminates the need for pill-splitting and supports improved treatment outcomes during childhood development.

June 2025 also brought several groundbreaking trials and new updates in diabetes care at the 8th American Diabetes Association Scientific Sessions, which were held in Chicago, Illinois from June 20-23, 2025. With multiple sessions dedicated to late-breaking research, the meeting featured multiple simultaneous publications, including a slew of studies related to incretin therapies. To learn more about the meeting’s top news, check out this trio of articles recapping ADA 2025.

ADA 2025 Recap: 5 Studies on Obesity to Know

HCPLive Five at ADA Scientific Sessions 2025

Diabetes Dialogue: Semaglutide for MASH in ESSENCE Trial, With Arun Sanyal, MD

In this episode, the hosts discuss new Phase 3 data from the ESSENCE trial showing that once-weekly semaglutide 2.4 mg significantly improved liver outcomes and reduced weight in patients with MASH and stage 2 or 3 fibrosis. They speak with the trial’s lead author about semaglutide’s clinical impact, its potential as a future MASH treatment, and how it compares to the currently approved option, resmetirom.

In this episode, the hosts recap key moments from the 2025 AACE Annual Meeting, covering major plenaries, hands-on tech workshops, and the launch of a new diabetes technology certification program. They spotlight updates on GLP-1 safety, health equity, CGM innovations, and emerging trial data, while reflecting on the future of personalized diabetes care.

Diabetes Dialogue: Real-World Impact of iLet Bionic Pancreas, With Steven Russell, MD, PhD

In this episode, the hosts speak with the Chief Medical Officer of Beta Bionics about real-world outcomes from the iLet Bionic Pancreas, an FDA-cleared fully autonomous insulin delivery system requiring no user settings. They highlight its strong A1c-lowering effect, minimal hypoglycemia, and promise for underserved populations and primary care use, including off-label applications in type 2 diabetes.

Diabetes Dialogue: REDEFINE 1 and REDEFINE 2, with Timothy Garvey, MD, and Melanie Davies, MD

In this episode recorded at ADA 2025, the hosts break down results from the REDEFINE 1 and 2 trials showing that CagriSema delivered substantial weight loss and glycemic improvements in people with and without type 2 diabetes. They also discuss the drug’s safety, clinical relevance, and future in obesity care with trial investigators, highlighting upcoming studies like REDEFINE 3.

The second quarter of 2025 saw significant advancements in endocrinology, marked by FDA approvals and clinical breakthroughs. Key developments included the clearance of Dexcom's G7 15-day CGM system, expanded indications for osilodrostat in Cushing's syndrome, and the acceptance of Novo Nordisk's NDA for oral semaglutide for obesity. The ADA Scientific Sessions in June highlighted new data on incretin therapies and diabetes technology, with potential practice-changing implications. These updates underscore the evolving landscape of endocrine care, offering new treatment options and improved management strategies for various conditions.

Explore key advancements in endocrinology from Q2 2025, including FDA approvals and groundbreaking diabetes research shaping future treatments.

Q2 2025 Recap: Endocrinology News and Updates

HCPLive Endocrinology 
Month in Review: June 2025

June 2025 brought a wave of high-impact updates across 

, with new data and expert perspectives emerging from 3 of the field’s most influential meetings—ERA 2025, Heart in Diabetes, and the American Diabetes Association Scientific Sessions. From chronic kidney disease (CKD) to cardiometabolic care and next-generation therapies for diabetes and obesity, the month was packed with developments that could influence practice in both primary and specialty care.

Whether you missed the conferences or just need a refresher, here’s a quick look at the biggest storylines and standout updates from a pivotal month in endocrine medicine.

CONFIDENCE: SGLT2i and Finerenone Effective, Safe to Initiate Simultaneously in CKD

Results from the CONFIDENCE trial showed simultaneous initiation of finerenone (Kerendia) and empagliflozin (Jardiance) was well-tolerated and led to a 52% reduction in urinary albumin-to-creatinine ratio (UACR), significantly outperforming either therapy alone in patients with CKD and type 2 diabetes. Based on data from 800 patients, combination therapy reduced UACR 29% more than finerenone alone and 32% more than empagliflozin alone. According to investigators, this supports early combination use to enhance kidney and cardiovascular protection.

Kidney Compass: CONFIDENCE Trial at ERA 2025, with Rajiv Agarwal, MD, MS

19 Trial Meta-Analysis Finds GLP-1 RAs Have Substantial Kidney Benefits

A meta-analysis presented at ERA 2025 evaluated 19 randomized controlled trials (n=90,882) and found that GLP-1 receptor agonists significantly reduced the risk of composite renal outcomes by 19% and slowed eGFR decline. These agents also improved secondary endpoints, including a 24% reduction in microalbuminuria, 15% fewer major adverse cardiovascular events, and a 14% reduction in all-cause mortality. The findings were consistent across trials with low risk of bias, primarily involving diabetic patients.

Comparing Screening Methods for Heart Failure in Patients with Diabetes, with Mohammad Shahzeb Khan, MD

 in Philadelphia, PA, Mohammad Shahzeb Khan, MD, an assistant professor of medicine at Baylor College of Medicine, presented the results from his pooled cohort analysis comparing methods of measuring risk of heart failure in patients with type 2 diabetes without atherosclerotic cardiovascular disease.

Leveraging SGLT2 Inhibitors, GLP-1 RAs in Heart Failure, with Jose Lopez, MD

Once viewed solely as glucose-lowering agents for 

, sodium-glucose co-transporter 2 (SGLT2) inhibitors and GLP-1 RAs have emerged as powerful tools in the management of 

. In this interview, Jose Lopez, MD, discusses the evolving understanding of the utility of SGLT2 inhibitors and GLP-1 RAs in heart failure care, including both HFpEF and HFrEF.

The 85th American Diabetes Association Scientific Sessions delivered impactful data, with actionable implications for patient care today and in the future. Held from June 20-23, 2025, the meeting drew thousands of care providers from the US and abroad to in Chicago, Illinois. The meeting featured more than half a dozen simultaneous publications in major journals, including The Lancet and The New England Journal of Medicine. Use this link to check out all of 

, including late-breaking trial recaps, investigator interviews, and exclusive expert-led podcast episodes.

Check out our preview of our trials recap below!

Zimislecel Enables Insulin Independence in 10 Participants with Type 1 Diabetes

ACHIEVE-1: Oral GLP-1 Agonist Orforglipron Shows Strong HbA1c, Weight Reductions

BELIEVE: Bimagrumab + Semaglutide Combo Yields Substantial Fat-Mass Weight Loss, Preserves Lean Mass

Once-Monthly Obesity Drug, MariTide, Achieves Weight Loss Up to 16% at 1 Year

CATALYST Trial: Mifepristone Improves Glycemic Control in Type 2 Diabetes with Hypercortisolism

QWINT-1: Weekly Insulin Efsitora Matches Daily Basal Insulin in Type 2 Diabetes

ADA 2025: CagriSema Demonstrates Dual Benefit in Obesity and Type 2 Diabetes

As part of our continued coverage of updates in diabetes care and endocrinology, our flagship endocrinology podcast coverage the latest updates and headlines in the field. During the month of June, this culminated in the release of 8 new episodes, including 5 on-site recordings at ADA 2025. Check out our recap below to learn more about each episode:

American Diabetes Association Consensus Report on MASLD

CATALYST Trial, Mifepristone, and Hypercortisolism in T2D, with John Buse, MD, PhD

REDEFINE 1 and REDEFINE 2, with Timothy Garvey, MD, and Melanie Davies, MD

Addressing America's Shortage of Diabetes Care Providers, with Jay Shubrook, DO, & Conan Tu, MD

Updates from Dexcom at ADA 2025, with Kevin Sayer

The Diabetes Collective, with Rachael Sood, RN, MSN, APRN

May 2025 Diabetes Tech & Breakthrough T1D Updates

June 2025 was pivotal for endocrinology, with significant updates from ERA 2025, Heart in Diabetes, and the American Diabetes Association Scientific Sessions. Key findings included the CONFIDENCE trial's support for simultaneous use of finerenone and empagliflozin in CKD, and a meta-analysis highlighting GLP-1 receptor agonists' renal benefits. The Heart in Diabetes conference emphasized SGLT2 inhibitors and GLP-1 RAs in heart failure management. The ADA sessions presented impactful data on diabetes therapies, including insulin independence and weight loss advancements, with extensive coverage through podcasts and expert discussions.

June 2025 highlights groundbreaking advancements in endocrinology, featuring key insights from major conferences on diabetes, heart health, and kidney care.